2096.HK

Simcere Pharmaceutical Group Limited [2096.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

2096.HK Stock Summary

Earnings have grown 26.39% per last year.

The Moving Average Convergence Divergence (MACD) for 2096.HK recently turned positive (within last 10 days).

Top 10 Correlated Stocks

2096.HK

In the News

2096.HK Financial details

Company Rating

Market Cap

13.65B

Income

3.14B

Revenue

Book val./share

Cash/share

Dividend

0.18

Dividend %

2.98%

Employees

7.03K

Optionable

Shortable

Yes

Earnings

29 Mar 2024

P/E

17.13

Forward P/E

PEG

1.6

P/S

3.83

P/B

1.7

P/C

P/FCF

42.44

Quick Ratio

0.98

Current Ratio

2.35

Debt / Equity

LT Debt / Equity

EPS (TTM)

1.2

EPS next Y

EPS next Q

EPS this Y

-31.03%

EPS next Y

EPS next 5Y

EPS last 5Y

7.39%

Revenue last 5Y

6.96%

Revenue Q/Q

EPS Q/Q

SMA20

7.23%

SMA50

21.93%

SMA100

24.26%

Inst Own

Inst Trans

ROA

ROE

11%

ROC

0.05%

Gross Margin

79%

Oper. Margin

12%

Profit Margin

22%

Payout

49%

Shs Outstand

Shs Float

Target Price

52W Range

4.94-10.42

52W High

-12.4%

52W Low

+119%

RSI

Rel Volume

0.78

Avg Volume

4.77M

Volume

3.72M

Perf Week

14.36%

Perf Month

11.59%

Perf Quarter

26.04%

Perf Half Y

20.5%

Beta

0.458

Volatility

0.1%, 0.43%

Prev Close

0.34%

Price

8.76

Change

0.57%

2096.HK Financial Performance

2096.HK Dividend History

2096.HK Frequently Asked Questions

What is Simcere Pharmaceutical Group Limited stock symbol ?

Simcere Pharmaceutical Group Limited is a CN stock and trading under the symbol 2096.HK

What is Simcere Pharmaceutical Group Limited stock quote today ?

Simcere Pharmaceutical Group Limited stock price is $8.76 today.

Is Simcere Pharmaceutical Group Limited stock public?

Yes, Simcere Pharmaceutical Group Limited is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 4.77M
Market Capitalization 13.65B
Employee 7.03K
CEO Mr. Jinsheng Ren
Headquarters Nanjing,CN
IPO Date 2020-10-27
Website https://www.simcere.com

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.